Stereotactic Comparison Study of 18F-Alfatide and 18F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model

This study aimed to stereotactically compare the PET imaging performance of F-18-Alfatide (F-18-ALF-NOTA-PRGD(2), denoted as F-18-Alfatide) and F-18-fluorodeoxyglucose (FDG) and immunohistochemistry (IHC) staining in Lewis lung carcinoma (LLC) tumor-bearing C57BL/6 mouse model. F-18-FDG standard uptake values (SUVs) were higher than F-18-Alfatide SUVs in tumors, most of the normal tissues and organs except for the bladder. Tumor-to-brain, tumor-to-lung, and tumor-to-heart ratios of F-18-Alfatide PET were significantly higher than those of F-18-FDG PET (P < 0.001). The spatial heterogeneity of the tumors was detected, and the tracer accumulation enhanced from the outer layer to the inner layer consistently using the two tracers. The parameters of the tumors were significantly correlated with each other between F-18-FDG SUV and GLUT-1 (R = 0.895, P < 0.001), F-18-Alfatide SUV and alpha v beta 3 (R = 0.595, P = 0.019), F-18-FDG SUV and F-18-Alfatide SUV (R = 0.917, P < 0.001), and GLUT-1 and alpha v beta 3 (R = 0.637, P = 0.011). Therefore, F-18-Alfatide PET may be an effective tracer for tumor detection, spatial heterogeneity imaging and an alternative supplement to F-18-FDG PET, particularly for patients with enhanced characteristics in the brain, chest tumors or diabetes, meriting further study.